Research Area
Product Type
United States ( Change Country )
PHA-793887 Chemical Structure
Recommended Products
PD 0332991 HCl
PD 0332991 is a highly selective inhibitor of Cdk4/cyclin D1 and Cdk6/cyclin D2 with IC50 of 11 nM and 16 nM, respectively.
SNS-032 (BMS-387032)
SNS-032 (BMS-387032) is a potent and selective cyclin-dependent kinases (CDK) 9, 7 and 2 inhibitor with IC50 of 4, 62 and 38 nM for CDK9, CDK2/cyclin A and CDK7/Cyclin H.
Roscovitine (Seliciclib, CYC202)
Roscovitine (Seliciclib, CYC202, R-roscovitine) is a potent and selective inhibitor of the cyclin-dependent kinases with IC50 of 0.65, 0.7, 0.7 and 0.16 μM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E and cdk5/p53, respectively.
Flavopiridol (Alvocidib)
Flavopiridol (Alvocidib) is a pan-cdk inhibitor. Flavopiridol is a potent inhibitor of CDKs 1, 2 and 4 in cell-free assays (IC50 in the region of 100 nM) and tumour cell growth in vitro (typical IC50 in the region of 100 nM). Flavopiridol inhibited rhabdoid cell growth (IC50 of 200nmol/L).
JNJ-7706621
JNJ-7706621 is a novel, potent, and broad-spectrum inhibitor of CDK and Aurora kinases including CDK1/Cyclin B, CDK2/Cyclin A, CDK2/Cyclin E, Aurora-A and Aurora-B with IC50 of 9 nM, 4 nM, 3 nM and 11 nM, respectively.
AT7519
AT7519 is a kinase inhibitor with IC50 of 0.19, 0.044, 0.51, 0.067, 0.66 and 0.018 μM for CDK1/cyclinB, CDK2/CyclinA, CDK2/Cyclin E, CDk4/CyclinD1, CDK6/Cyclin D3, CDk5/p35.
BS-181 HCl
BS-181 is a highly selective cyclin-dependent kinase (CDK) inhibitor of CDK7 activity with IC50 of 21 nM.
Mubritinib (TAK 165)
Mubritinib (TAK 165) is a potent EGFR and p34cdc2 inhibitor with IC50 of 6 nM and 0.2 μM, respectively
AZD5438
AZD5438 is a potent cyclin-dependent kinase (cdk) 1, 2 and 9 inhibitor with IC50 of 16, 6 and 20 nM, respectively.
Biological Activity
PHA-793887 is a novel pan-cdk inhibitor, including cdk1, cdk2, cdk4, cdk5, cdk7, and cdk9 with IC50 in the 5 to 140 nM range. [1]It is inactive against other 34 kinases representative of all kinase families, in particular c-abl, c-kit, lck, and TRKA with IC50＞10 mM. It shows anti-proliferative activity against several solid tumor cell lines, with IC50＜1 mM. In these cells, it is able to inhibit Rb phosphorylation and expression of S-phase cyclins, such as cyclin A. [1,2]
References on PHA-793887
- [1] Mol Cancer Ther 2010;9:1265-1273
- [2] Experimental Hematology 2010 ;38:259–269
Chemical Information
| Molecular Weight (WM): | 361.48 |
|---|---|
| Formula: | C19H31N5O2 |
| CAS No.: | 718630-59-2 |
| Synonyms: |
N/A
|
| Dissolve in (25°C): | DMSO ≥72mg/mL |
| Water <1mg/mL | |
| Ethanol ≥72mg/mL | |
| Storage: | 2 years-20°CPowder |
| 1 week-4°Cin DMSO | |
| 1 month-80°in DMSO |
Quality Control & MSDS
Research Area
Notes:
Related Inhibitors
Recommended Screening Libraries
Chemical Library
A collection of 864 bioactive compounds
Inhibitor Library
A collection of 481 inhibitors
Kinase Inhibitor Library
A collection of 194 kinase inhibitors
Tyrosine Kinase Inhibitor Library
A collection of 85 tyrosine kinase inhibitors.
FDA Approved Drug Library
A collection of 426 FDA approved drugs
Natural Product Library
A collection of 139 natural products
Chemotherapeutic Agent Library
A collection of 40 chemotherapeutic agents
Epigenetics Compound library
A unique collection of 17 small molecule modulators
Stem Cell Compound library
A unique collection of 47 small molecule inhibitors
GPCR Compound library
A unique collection of 63 GPCR small molecules
Keywords:buy PHA-793887 | PHA-793887 supplier | purchase PHA-793887 | PHA-793887 cost | PHA-793887 manufacturer | order PHA-793887 | PHA-793887 distributor